Bristol ends Corgentech collaboration
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb is terminating a development agreement with Corgentech for the coronary artery bypass graft agent edifoligide (E2F decoy). The agent failed to meet primary or secondary endpoints in a Phase III vein graft failure study, the firms say March 30. Corgentech has no further development plans for edifoligide beyond completing an ongoing Phase I trial. The company will instead focus on a NF-kappaB decoy for eczema...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.